Three Elite Growth Companies With Significant Insider Ownership

As global markets navigate a holiday-shortened week, characterized by moderate gains and fluctuations in consumer confidence and jobless claims, investors are increasingly focused on growth opportunities. In this context, companies with significant insider ownership often attract attention due to the alignment of interests between management and shareholders, which can be particularly compelling during times of economic uncertainty.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Seojin SystemLtd (KOSDAQ:A178320)	30.9%	39.9%
People & Technology (KOSDAQ:A137400)	16.4%	37.3%
SKS Technologies Group (ASX:SKS)	29.7%	24.8%
Medley (TSE:4480)	34%	31.7%
Laopu Gold (SEHK:6181)	36.4%	34.2%
Plenti Group (ASX:PLT)	12.8%	120.1%
Brightstar Resources (ASX:BTR)	16.2%	84.5%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	131.1%
HANA Micron (KOSDAQ:A067310)	18.5%	110.9%
Findi (ASX:FND)	34.8%	112.9%

Click here to see the full list of 1501 stocks from our Fast Growing Companies With High Insider Ownership screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Pharmanutra (BIT:PHN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pharmanutra S.p.A. is a pharmaceutical and nutraceutical company that researches, designs, develops, and markets nutritional supplements and medical devices across Italy, Europe, the Middle East, South America, the Far East, and internationally with a market cap of €522.67 million.

Operations: The company's revenue is segmented into €5.49 million from Akern, €68.35 million from Italy, and €38.40 million from international markets outside Italy.

Insider Ownership: 10.7%

Earnings Growth Forecast: 18.5% p.a.

Pharmanutra has demonstrated strong growth, with earnings rising 36.3% over the past year and a forecasted annual profit growth of 18.5%, outpacing the Italian market's 7%. The company's revenue is expected to grow at 13.2% annually, surpassing the local market's rate of 4%. Recent earnings reports show increased sales and net income for the nine months ending September 2024, indicating robust operational performance. Analysts predict a potential stock price increase of 55%.

• Navigate through the intricacies of Pharmanutra with our comprehensive analyst estimates report here.
• The analysis detailed in our Pharmanutra valuation report hints at an inflated share price compared to its estimated value.

Tabuk Cement (SASE:3090)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Tabuk Cement Company manufactures and sells cement in the Kingdom of Saudi Arabia, with a market cap of SAR1.16 billion.

Operations: The company's revenue is derived from its Packed and Unpackaged Cement segment, amounting to SAR328.89 million.

Insider Ownership: 16.4%

Earnings Growth Forecast: 21.6% p.a.

Tabuk Cement reported Q3 2024 sales of SAR 90.12 million and net income of SAR 23.05 million, with earnings per share at SAR 0.26. The company is trading significantly below its estimated fair value and forecasts suggest a strong annual profit growth rate of 21.6%, outpacing the SA market's average growth rate. However, revenue growth is expected to be moderate at 4.9% annually, and return on equity is projected to remain low at 7.1%.

• Take a closer look at Tabuk Cement's potential here in our earnings growth report.
• Insights from our recent valuation report point to the potential undervaluation of Tabuk Cement shares in the market.

Medley (TSE:4480)

Simply Wall St Growth Rating: ★★★★★★

Overview: Medley, Inc. operates platforms for recruitment and medical businesses in Japan and the United States, with a market cap of ¥124.58 billion.

Operations: The company's revenue is primarily derived from its Human Resource Platform Business, generating ¥19.45 billion, followed by the Medical Platform Business at ¥6.52 billion, and New Services contributing ¥713 million.

Insider Ownership: 34%

Earnings Growth Forecast: 31.7% p.a.

Medley is positioned for substantial growth, with its revenue expected to increase by 22.4% annually, surpassing the JP market's average. Earnings are also projected to grow significantly at 31.67% per year, well above the market rate. Despite a highly volatile share price recently and large one-off items affecting earnings quality, Medley is trading at nearly half its estimated fair value. Recent strategic moves include acquiring ASFON TRUST NETWORK and divesting MEDiPASS Co., Ltd.

• Click to explore a detailed breakdown of our findings in Medley's earnings growth report.
• According our valuation report, there's an indication that Medley's share price might be on the expensive side.

Seize The Opportunity

• Investigate our full lineup of 1501 Fast Growing Companies With High Insider Ownership right here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com